Medical Meeting Webcast

Opening the Window of Opportunity: Strategies for Successful Treatment and Management of Patients with Crohn’s Disease

Launch Date
05/25/2021
Credit Amount
0.00 Expired
Credit Expires
05/25/2022

Faculty

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.

Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
James F. Heady Endowed Chair and Professor of Medicine
Executive Vice Chair of Internal Medicine
Department of Internal Medicine
Division of Digestive Diseases
University of Cincinnati College of Medicine
Associate Chief Medical Officer
UC Health System
Cincinnati, OH
Millie D. Long, MD, MPH
Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology
University of North Carolina 
Chapel Hill, NC 
Millie D. Long, MD, MPH

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the American Journal of Gastroenterology. She also serves as an invited reviewer for journals such as Inflammatory Bowel Diseases and Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Crohn’s disease (CD) is characterized by transmural inflammation and systemic, extraintestinal manifestations that can cause a range of clinical presentations. Traditional management of CD is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, which does not improve long-term outcomes in CD and also increases risk for bowel damage. On the other hand, incorporating elements of prognosis into treatment decisions and implementing treat-to-target and tight-control treatment strategies using appropriate therapies can significantly improve patient outcomes.

This CME Outfitters webcast will feature expert faculty leading a case-based discussion that focuses on applying prognosis to treatment decisions, choosing optimal treatment strategies, differentiating targeted therapies, and engaging patients with CD in shared decision-making.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Differentiate biologic therapies in CD based on their mechanisms of action (MOAs), efficacy, safety, and ability to induce rapid and durable treatment response.
  • Incorporate elements of prognosis into treatment decisions in CD based on clinical research data and guideline recommendations.
  • Implement strategies to engage all patients with CD in shared decision-making with the goal of increasing patient satisfaction, clinical outcomes, and treatment adherence.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Differentiate biologic therapies in CD based on their MOAs, efficacy, safety, and ability to induce rapid and durable treatment response.
  • Explain elements of prognosis for treatment decisions in CD based on clinical research data and guideline recommendations.
  • Describe strategies to engage all patients with CD in shared decision-making with the goal of increasing patient satisfaction, clinical outcomes, and treatment adherence.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-127-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rubin reports that he receives grants from Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Bellatrix Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CDx Diagnostics; Celgene Corporation/Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; Ichnos Sciences SA; InDex Pharmaceuticals; Iterative Scopes, Inc.; Janssen Pharmaceuticals, Inc.; Materia Prima; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is on the board of trustees for American College of Gastroenterology; Co-Founder, CFO of Cornerstones Health, Inc. (non-profit) and Co-Founder of GoDuRn, LLC.

Dr. Afzali reports that she serves on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.

  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-127-H01-P

 

MMV-114-052521-90

Opening the Window of Opportunity: Strategies for Successful Treatment and Management of Patients with Crohn’s Disease
Event Date: 05/25/2021